Merck KGaA taps UK cancer research organizations to feed pipeline
After an R&D drought that lasted more than a decade, Merck KGaA may be coming out of the desert. Following two recent drug approvals, including the landmark FDA OK for checkpoint inhibitor Bavencio, the German Merck is now entering an R&D collaboration that might help fill its pipeline with new cancer drug contenders.
The company is teaming up with Cancer Research UK and the Institute of Cancer Research, London for three research projects and a licensing deal. The group will be doing discovery-stage work looking for targets and preclinical candidates.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.